Article

Breast cancer and long-term hormonal treatment of male hypogonadism.

Department of Endocrinology, Diabetology and Nuclear Therapy, Wroclaw Medical University, Wroclaw, Poland.
Breast Cancer Research and Treatment (impact factor: 4.43). 05/2006; 96(3):263-5. DOI:10.1007/s10549-005-9074-y
Source: PubMed

ABSTRACT Breast cancer in men is rare and its etiology is multifactorial. Androgens may promote the development of breast carcinoma in men though data on the subject is scarce. We observed 45 men with hypergonadotropic hypogonadism (aged 18-57) who received 250 mg of testosterone esters (Omnadren 250, Jelfa, Poland) every 3-4 weeks for 5-26 years. Seventeen of them were treated for more than 10 years. During the observation period breast cancer was diagnosed in 2 subjects (11% of the followed men). In one case it occurred after 11 years and in the other after 15 years of the therapy. We point to a possible association between long-term androgen replacement and a risk of breast cancer in men.

0 0
 · 
0 Bookmarks
 · 
24 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Keywords

2 subjects
 
3-4 weeks
 
Androgens
 
breast cancer
 
breast carcinoma
 
long-term androgen replacement
 
observation period breast cancer
 
possible association
 
testosterone esters